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Background and aim: Hepatitis E virus (HEV) is a 
virus of emerging importance to transfusion medi-
cine. Studies from several European countries, includ-
ing Switzerland, have reported high seroprevalence 
of hepatitis E as a consequence of endemic infec-
tions. Published HEV seroprevalence estimates within 
developed countries vary considerably; primarily 
due to improved diagnostic assays. The purpose of 
this study was to investigate the seroprevalence of 
anti-HEV IgG in Swiss blood donations.  Methods:  We 
used the highly sensitive Wantai HEV IgG EIA and 
assessed regional distribution patterns. We ana-
lysed age- and sex-matched archive plasma dating 
back 20 years from canton Bern to investigate recent 
changes in HEV seroprevalence levels.  Results:  On 
average, 20.4% (95% confidence intervals: 19.1–21.8) 
of the 3,609 blood samples collected in 2014–16 were 
anti-HEV IgG positive; however, distinct differences 
between geographical regions were observed (range: 
12.8–33.6%). Seroprevalence increased with age 
with 30.7% of males and 34.3% of women being posi-
tive donors over  >  60 years old. Differences between 
sexes may be attributed to dissimilarities in the aver-
age age of this group. Within the specified region of 
the Bern canton, overall prevalence has declined over 
two decades from 30.3% in 1997/98 to 27.0% in 2006 
and 22.3% in 2015/6. Conclusions: HEV seroprevalence 
in Switzerland is high, but has declined over the last 
decades. The result shows that primarily endemic 
HEV infections occur and that current blood products 
may pose a risk to vulnerable transfusion recipients. 
Nucleic acid screening of all blood products for HEV 
will begin in November 2018.
Introduction
Hepatitis E virus (HEV), is a small, non-enveloped virus 
belonging to the family Hepevirus, was first described 
in 1978 during a non-A non-B hepatitis outbreak in the 
Kashmir region of the Indian subcontinent [1,2]. There 
are four major HEV genotypes (HEV G1–4) that can 
infect humans. Genotypes 1 and 2 only infect humans, 
are transmitted primarily by a faecal-oral route or con-
taminated water, and were likely responsible for the 
first described outbreaks. For more than a decade it 
has been recognised that autochthonous infections 
with HEV genotype 3 are common in some industrial-
ised countries [3,4]. Although the transmission routes 
are not yet completely understood, it is thought that 
domesticated swine, wild boar and deer are reservoirs 
for the zoonotic HEV genotype 3 strains and a likely 
source of human infection through the consumption of 
uncooked meat, shellfish, vegetables and berries [5-8]. 
In most cases the infection, especially in immunocom-
petent individuals, is asymptomatic [9]. The symp-
tomatic clinical signs of an acute HEV infection are 
nausea, vomiting, malaise, loss of appetite and jaun-
dice (similar clinical presentation as classic hepatitis 
infection), but protracted neurological signs can also 
develop, particularly for genotype 3 [10]. Most infec-
tions are self-limiting but can, in exceptional cases, 
develop into a life-threatening fulminant hepatitis, par-
ticularly in pregnant women infected with genotype 1 
and 2, or in immunocompromised patients infected with 
genotype 3 [11]. The HEV infection may also develop 
into a chronic infection in immunocompromised indi-
viduals [12]; this has been primarily observed in solid 
organ recipients, but has also been reported in other 
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immunosuppressed individuals receiving numerous 
blood components [13].
Transfusion transmission of HEV was previously 
described with genotype 1 [14] and, more recently, HEV 
transmission with genotype 3 was reported in several 
European countries [15,16]. Prevalence of HEV viraemia 
in donors has been reported to range from 1:762 in 
the Netherlands to 1:9,500 in the United States [17,18], 
highlighting the potential for a higher risk of HEV 
transmission from contaminated blood products than 
previously assumed, particularly to vulnerable immu-
nosuppressed recipients.
In recent years, a number of published data have 
indicated a wide variation in HEV seroprevalence in 
Europe, ranging from 1.9% in Switzerland to 86.4% in 
France [19,20]. The reason for this wide variation is not 
entirely clear, but it could be a consequence of many 
factors, such as eating habits, differences in food pro-
duction, age of the tested population, country or region 
of residence or sex. Furthermore, the variable perfor-
mance of different anti-HEV IgG assays has hindered a 
direct comparison of the various data.
HEV is currently not a notifiable infectious disease in 
Switzerland and as a result HEV infections are prob-
ably under-diagnosed as they are either not reported 
or missed due to the common asymptomatic or mild 
symptomatic presentation. In addition, symptoms 
compatible with an HEV infection have, until recently, 
been attributed to a variety of other causes including 
other viral agents, drug-related or autoimmune hepa-
titis, ischaemic hepatopathy, hepatic graft-versus-host 
reaction after stem cell transplantation, or rejection or 
surgical complication after liver transplantation.
Figure 1
Regional distribution of hepatitis E IgG seroprevalence in blood donors, Switzerland, August 2014–February 2016 (n = 3,609)
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AG/SO: Aargau/Solothurn; BeJU/JU/NE: Berner Jura/Jura/Neuchâtel; BE: Bern; BS/BL: Basel-Stadt/Basel-Landschaft; FR: Fribourg; GE: Genève; 
LU: Luzern; NW/OW: Nidwalden/Obwalden; SG/AI/AR: St. Gallen/Appenzell Innerrhoden/Appenzell Ausserrhoden; TG: Thurgau; TI: Ticino; UR: 
Uri; VD: Vaud; VS: Valais.
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The purpose of this study was to investigate the cur-
rent and past seroprevalence of anti-HEV IgG in 
Switzerland and to assess the regional distribution 
patterns. Furthermore, this study aimed to increase 
the clinicians’ awareness of HEV infection through con-
taminated food products, transplantations and blood 
products, as well as to provide rationale for a possi-
ble prospective nationwide HEV donation screening 
strategy.
Methods
Regional distribution of HEV seroprevalence in 
Swiss blood donors, 2014–2016
Between August 2014 and February 2016, a total 
of 3,609 EDTA plasma samples were collected from 
unlinked, unpaid, volunteer blood donors from 20 of the 
26 Swiss cantons, including 10 of the 12 regional Blood 
Transfusion Services (BTS) (Figure 1). Two BTS repre-
senting six cantons declined to join the study. However, 
as all the major geographical regions (e.g. alpine, val-
ley, towns, cities and country borders) encountered in 
Switzerland are covered by the 20 cantons included in 
this study, the results are considered generalisable to 
the whole country. The presence of HEV-specific IgG 
antibodies were assessed using the anti-HEV IgG assay 
(WANTAI HEV-IgG ELISA, Eurobio, Les Ulis, France), 
according to the manufacturer’s instructions, on a 
BEPIII Behring ELISA processor (Siemens Healthcare 
Diagnostics, Marburg, Germany). The Wantai HEV IgG 
EIA has been reported to be the most sensitive and 
specific [21,22]. Results are expressed as signal-to-
cut-off (s/co) value; samples with an s/co value  <  0.9 
were considered negative and those with an s/co 
value  ≥  2 were considered positive. Those with s/co 
values between 0.9 and 2.0 were retested in duplicate 
and were considered positive if s/co > 1.1, negative if s/
co < 0.9 or borderline if s/co was between 0.9 and 1.1 in 
two of the three replicates, respectively. The age and 
sex of the donors was obtained from the corresponding 
regional BTS donor database.
According to Swissmedic, the federal authority respon-
sible for the notification of blood components, sepa-
rate donor consent for testing HEV IgG antibodies in 
blood donors was not required as it is included in the 
current donor consent form.
Retrospective study of HEV seroprevalence in 
blood donors from Bern canton, 1997/1998, 
2006, 2015/2016
The anti-HEV IgG seroprevalence (WANTAI HEV-IgG 
ELISA) among blood donors from Bern canton in 
1997/98 (August 1997–November 1998) and 2006 
(January–December) was determined on archival sam-
ples stored at -30 °C, using the same test criteria as the 
assessment of regional HEV seroprevalence described 
previously. From each period, 400 donor samples that 
were equally distributed within Bern canton, were 
selected to match the age and sex in 10 age catego-
ries with the 400 donor samples collected in 2015/16 
(September 2015–June 2016).
Table 1
Regional distribution of hepatitis E IgG prevalence in blood donors, Switzerland, August 2014–February 2016 (n = 3,609)
Region
IgG positive IgG borderline IgG negative
Total number 
of donationsNumber of 
donations Prevalence (95% CI)
Number of 
donations
Prevalence 
(95% CI)
Number of 
donations
Prevalence (95% 
CI)
GE 24 12.8 (8.7–18.3) 0 0.0 (0.0–2.0) 164 87.2 (81.7–91.3) 188
UR 20 12.9 (8.5–19.1) 2 1.3 (0.4–4.6) 133 85.8 (79.4–90.4) 155
AG/SO 30 13.3 (9.5–18.3) 1 0.4 (0.1–2.5) 195 86.3 (81.2–90.2) 226
NW/OW 58 15.6 (12.3–19.6) 0 0.0 (0.0–1.0) 314 84.4 (80.4–87.7) 372
LU 28 16.0 (11.3–22.2) 0 0.0 (0.0–2.1) 147 84.0 (77.8–88.7) 175
FR 39 18.4 (13.8–24.2) 1 0.5 (0.1–2.6) 172 81.1 (75.3–85.8) 212
BeJU/JU/NE 51 19.5 (15.1–24.7) 1 0.4 (0.1–2.1) 210 80.2 (74.9–84.5) 262
VS 39 19.5 (14.6–25.5) 3 1.5 (0.5–4.3) 158 79.0 (72.8–84.1) 200
TG 39 20.2 (15.1–26.4) 1 0.5 (0.1–2.9) 153 79.3 (73.0–84.4) 193
SG/AI/AR 63 21.5 (17.2–26.6) 3 1.0 (0.3–3.0) 227 77.5 (72.4–81.9) 293
VD 91 22.2 (18.5–26.5) 1 0.2 (0.0–1.4) 317 77.5 (73.2–81.3) 409
BS/BL 56 23.3 (18.4–29.1) 3 1.3 (0.4–3.6) 181 75.4 (69.6–80.4) 240
BE 69 24.8 (20.1–30.2) 1 0.4 (0.1–2.0) 208 74.8 (69.4–79.6) 278
TI 116 33.6 (28.8–38.8) 2 0.6 (0.2–2.1) 227 65.8 (60.6–70.6) 345
Other origin 14 23.0 (14.2–34.9) 0 0.0 (0.0–5.9) 47 77.0 (65.1–85.8) 61
Total 737 20.4 (19.1–21.8) 19 0.5 (0.3–0.8) 2,853 79.1 (77.7–80.3) 3,609
AG/SO: Aargau/Solothurn; BeJU/JU/NE: Berner Jura/Jura/Neuchâtel; BE: Bern; BS/BL: Basel-Stadt/Basel-Landschaft; CI: confidence interval; 
FR: Fribourg; GE: Genève; LU: Luzern; NW/OW: Nidwalden/Obwalden; SG/AI/AR: St. Gallen/Appenzell Innerrhoden/Appenzell Ausserrhoden; 
TG: Thurgau; TI: Ticino; UR: Uri; VD: Vaud; VS: Valais.
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Statistical analysis
The prevalence of anti-HEV IgG antibodies and the 
95% confidence intervals (CI) according to Wilson 
method without continuity correction were calcu-
lated. Pearson’s chi-squared test was used to evaluate 
regional variations and the effect of age on the anti-HEV 
IgG seroprevalence. The same test was used to assess 
possible differences between the anti-HEV IgG preva-
lence rates in 1997/98, 2006 and 2015. Yates’ continu-
ity correction was applied to Pearson’s chi-squared test 
for pairwise comparisons of 2 years. In order to simul-
taneously assess the influence of the time (i.e. the 
year of the test) and the demographic characteristics, 
these analyses were complemented with multivariate 
analyses using logistic regression models for anti-HEV 
IgG prevalence rates during 1997/98, 2006 and 2015. 
Demographic characteristics incorporated in the mul-
tivariate analyses included age, sex and region of resi-
dence. A statistical significance was calculated and a 
p value of less than 0.05 was defined as a statistically 
significant difference. All calculations were conducted 
with the software R 3.3.1 (Ref R Core Team. 2016; R 
Foundation for Statistical Computing, Vienna;  http://
www.R-project.org).
Results
In total, there were 3,609 (m = 2,225, w = 1,384) blood 
samples collected from the 20 cantons in this study, 
with a mean number of tested blood donor samples of 
240 (range: 61–409). The median age of donors was 47 
years (interquartile range (IQR): 34–56; range: 17–76).
Regional distribution of HEV seroprevalence in 
Swiss blood donors, 2014–2016
The overall positive anti-HEV IgG seroprevalence 
among the 3,609 Swiss blood donors in 2015/16 was 
20.4% (95%CI: 19.1–21.8) (Table1). A statistically sig-
nificant variation in the HEV IgG seropositivity asso-
ciated with the different Swiss geographical regions 
(n = 3,609, 95%CI: 19.1–21.8: p < 0.001) was observed 
(Table 1 and Figure 1). The lowest levels were observed 
in the cantons of Geneva (n  =  24; 95% CI: 8.7–18.3) 
and Uri (n  =  20; 95% CI: 8.5–19.1), whereas in Ticino 
canton–the most southern canton situated below the 
Alps, the highest level was observed (n = 116; 95% CI: 
28.8–38.8).
The overall performance of the Wantai HEV IgG EIA was 
determined by the reproducibility of repeated testing 
of the samples, with s/co values consistently reported 
between 0.9 and 2.0. Most repeat results (n  =  133) 
corroborated the original result, whereas only 0.25% 
(n  =  10) were re-categorised as negative. The 0.5% 
(n  =  19) borderline samples were excluded from the 
statistical analysis.
In total, there were 2,217 men and 1,382 women donors, 
with the most frequent category aged between 51-60 
years (male: n = 653; female: n = 319) (Table 2).
A statistically significant steady increase in the HEV 
seroprevalence of donors (of both sexes) with age was 
observed, i.e. 8.5% in donors aged < 30 years to 30.7% 
in donors aged > 60 years (p < 0.001). The non-equiva-
lence in the average age of the male and female donors 
(male: 47 years, female: 43 years) could in part explain 
the observed difference between male donors 22.0% 
(20.3%–23.7%) and female donors 17.9% (15.9%–
19.8%) (Figure 2). 
Retrospective study of HEV seroprevalence in 
blood donors from Bern canton, 1997/1998, 
2006, 2015/2016
Archival plasma stored at -30 °C were analysed to deter-
mine if there was a difference in the HEV seroprevalence 
from Bern canton during the time periods of 1997/1998 
and 2015/2016. The seroprevalence increased with 
age in all years tested; however, the overall seropreva-
lence from all years declined significantly from 30.3% 
(95%CI: 26.0–35.0) in 1997/98 to 27.0% (95%CI: 
Table 2
Age distribution of male and female blood donors, 
Switzerland, August 2014–February 2016 (n = 3,599a)
Age group (years) Male Female
≤ 30 307 378
31-40 351 202
41-50 580 305
51-60 653 319
≥ 61 326 178
Total 2,217 1,382
aThe age of eight males and two females are unknown.
Figure 2
Age and sex distribution of hepatitis E IgG positive 
blood donors, Switzerland, August 2014–February 2016 
(n = 3,599a)
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22.9–31.6) in 2006 and 22.3% (95%CI: 18.5–26.6) 
in 2015/16 (Pearson chi-squared test over the three 
time points: p  =  0.027) (Figures 3  and  4). The analy-
sis revealed a significant difference between 1997/98 
and 2015/16 (p  =  0.0093), but between 1997/98 and 
2006 (and between 2006 and 2015/16) the difference 
was not significant (p > 0.05). Analysis of different age 
groups found a significant reduction in seroprevalence 
in the 40–50-year-old and  >  60-year-old age groups 
(p = 0.039 and p = 0.038, respectively). Furthermore, 
since the observed difference between the three time 
points could have been due to varying demographic 
characteristics, a logistic regression models were used 
in order to be able to analyse the simultaneous effect of 
three parameters (time, age, sex, and/or regional pre-
dictors) on the HEV seroprevalence. If only the time as 
a factor with three levels was used as an influence, the 
likelihood ratio (LR) test gave a p value = 0.026 for the 
influence of this factor (LR = 7.2977, df = 2). Assuming 
a linear trend (more precisely, a linear effect of the time 
on the logit of the probability of a positive result) over 
all three time points, a p value of 0.0072 (LR = 7.2232, 
df = 1) was obtained. When adding main effects of the 
sex and the age categories to this model, the effect 
of the time was still significant (LR  =  8.366, df  =  1, 
p = 0.0038). No significant interaction effects between 
the time, the sex, and the age groups were found. In 
extensions of the model with these three main effects 
(time, sex, and age category) that additionally included 
one of several possible predictors based on the place 
of residence, the p value of the LR test for the effect of 
the time was always between 0.001 and 0.008. Thus, 
a significant reduction in the HEV IgG seroprevalence 
over time was found in all the models used.
Discussion
Anti-HEV IgG seroprevalence data from various coun-
tries indicate that prior HEV infection has been increas-
ing during the last decade. This increase may reflect 
a real rise in HEV incidence, particularly in European 
countries, but could also be a reaction to an increased 
public health awareness of HEV infection acquired 
through zoonotic and food-borne transmission of HEV. 
The situation has been further complicated by the 
broad performance variation of the currently available 
commercial anti-HEV assays [23]. The Wantai HEV IgG 
EIA is regarded as one of the most sensitive and spe-
cific assays currently commercially available [21,22].
There have been a limited number of HEV seropreva-
lence studies on blood donations in Switzerland, but 
these have generally been restricted to a confined 
region, have tested a limited number of samples and 
have used less sensitive assays [24-26]. These reports 
revealed a wide difference in the seroprevalence 
(4.2%–21.8%), with no difference between male and 
female donors. This present study has revealed an 
overall seroprevalence of 20.4% (95%CI: 19.1–21.8), 
with significant differences between the regions 
tested. As expected from other published reports, the 
anti-HEV seroprevalence increased significantly with 
age. The overall seroprevalence difference observed 
between the sex of the donors is likely a consequence 
of the differing average age of these donors, however 
this observation was not supported in the multivariate 
analysis using time/age/sex simultaneously.
Figure 3
Overall anti-HEV IgG seroprevalence in a matched cohort 
of blood donor samples from the region of Bern canton, 
1997/98, 2006, 2015/16 (n = 400)
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Figure 4
Anti-HEV IgG seroprevalence by age in a matched cohort 
of blood donor samples from the region of Bern canton, 
1997/98, 2006, 2015/16 (n=1,200)
0
10
20
30
40
50
60
20 30 40 50 60 70
An
ti-
HE
V 
Ig
G 
se
ro
pr
ev
al
en
ce
 (%
)
Age (years)
1997/98
2006
2015/16
Vertical lines indicate 95% confidence intervals.
Age: averaged over 10-year age categories.
6 www.eurosurveillance.org
In many European countries similarly high seropreva-
lence differences have been recorded; for example, 
25%–86.4% in France and 21%–27% in the Netherlands 
[19,20,27,28]. Interestingly, the French Jura, a region 
directly adjacent to the west of Switzerland, has 
reported a similar seroprevalence to the one in our 
report [20]. High prevalence has not been observed in 
all industrialised countries, for example in Scotland, 
Canada and Australia prevalence did not exceed 6% 
[29,30], and within countries a considerable variation 
has often been observed. Variations in HEV IgG sero-
prevalence were also observed in our study (range: 
12.8%–33.6%) and we found that in some isolated 
districts within the Ticino canton it was bordering on 
60% (data not shown). It has been suggested that 
these large regional variations may be a consequence 
of the consumption of a regional delicacy of traditional 
raw dry-cured pork sausage containing raw pork liver 
(e.g.  mortadella di fegato crudo) [19,31]. It remains to 
be seen whether the variation in Switzerland can be 
explained by these dietary differences.
In some countries, notably Denmark, the Netherlands 
and the United States, the analysis of archived sam-
ples has suggested the seroprevalence has declined in 
recent decades [32-35], whereas other countries have 
reported an increase [36]. The analysis of 400 archived 
blood donor samples from Bern canton from 1997/98, 
2006 and 2015/16 showed a similar declining anti-HEV 
IgG prevalence from 30.3% in 1997/98 to 27.0% in 2006 
and 22.3% in 2015/16. The trends in seroprevalence in 
other studies has been questioned due to the differ-
ences in the sensitivities and specificities of the tests 
used [32,34]. Since the results presented here were all 
conducted with the same EIA, and often in the same 
experiment, the observed seroprevalence reduction 
over time appears to be real and may reflect a change 
in the level of contaminated food, which is regarded as 
the primary route of acquiring HEV infection. It remains 
to be seen whether the slight anti-HEV IgG increase in 
the most recent samples from the  <  30-years-old age 
group reflects an increase in the HEV infection of these 
individuals.
HEV seroprevalence studies are important to highlight 
the level of infections within a population and to con-
tribute to assessments of the epidemiological situation 
within the population. Likewise, HEV RNA incidence 
studies of blood donors contribute to the risk deter-
mination of HEV transmission via blood products. In 
Europe, incidences ranging from 1:600 to 1:15,000 have 
been recently reported [16,17,37], and several studies 
have documented HEV blood transfusion transmission 
[15,16,38,39]. Though many HEV transfusion-transmit-
ted infections are asymptomatic and self-limiting, par-
ticularly in immunocompetent patients, serious chronic 
infections can occur in immunosuppressed patients 
(e.g. solid organ and haematopoietic stem cell trans-
plant patients). It is often these patients who receive 
numerous blood products and are thus at greater risk to 
HEV infection. Several European countries (e.g. France, 
Ireland, the Netherland and the United Kingdom) [40] 
have already begun molecular screening of blood 
donations for HEV RNA in different formats (individual 
donation or minipools). In Switzerland, the seropreva-
lence data presented here have recently contributed to 
discussions within the Swiss blood transfusion com-
munity; together with the national health authority and 
clinical hepatologists, they have come up with recom-
mendations for future HEV molecular testing of blood 
donations and the consequent monitoring of at-risks 
patients. As a consequence of these discussions, from 
November 2018 all blood products will be mandatorily 
screened in Switzerland for HEV RNA in pools of 24 or 
less blood donations. The required detection limit in 
the individual donation was set at 450 HEV IU/ml.
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